AR and neoplasm: Numerous mechanisms have been demonstrated to drive disease progression upon AR-targeted therapy [13], of which the truncated and constitutively active AR variants (AR-Vs) due to alternative mRNA splicing have emerged as an important and common driver of drug resistance as they are frequently upregulated in castration-resistant vs. hormone-responsive tumor tissues [14,15,16,17,18].